

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1-12. (Canceled)

13. (Original) A method of selectively inhibiting an angiogenic process promoted by a first angiogenic factor and but not the angiogenesis process promoted by a second angiogenic factor, comprising administering to a cell exposed to both factors an effective amount of STC-1 or a variant thereof, wherein the STC-1 or a variant thereof inhibits at least one step of the angiogenic process promoted by the first angiogenic factor but not the second angiogenic factor.

14. (Original) The method of claim 13, wherein the first and second angiogenic factors both are capable of inducing endogenous expression of STC-1.

15. (Original) The method of claim 14, wherein the first angiogenic factor is hepatocyte growth factor.

16. (Original) The method of claim 14 or 15, wherein the second angiogenic factor is basic fibroblast growth factor.

17. (Original) The method of claim 13, wherein the first angiogenic factor is hepatocyte growth factor and the second angiogenic factor is vascular endothelial growth factor.

18. (Previously presented) The method of claim 13, wherein the step inhibited by STC-1 or variant thereof is cell migration and/or morphogenesis induced by or associated with exposure of the cell to the first angiogenic factor.

19. (Previously presented) The method of claim 13, wherein STC-1 or variant thereof does not substantially inhibit cell proliferation.

20. (Previously presented) The method of claim 13, wherein STC-1 or variant thereof does not substantially inhibit cell migration and/or morphogenesis induced by or associated with exposure of the cell to the second angiogenic factor.

21-29. (Canceled)